Despite its lack of specificity towards PGRMC1, AG-205 may remain attractive for its anti-mitotic, anti-migratory and anti-invasive activities [10] which stimulated hopes of therapeutic applications, as illustrated by the patent targeting breast cancer [13]. This evidence concerns the gene PGRMC1 and breast carcinoma.